FDA Approves LUSEDRA(TM) (fospropofol disodium) Injection for Monitored Anesthesia Care (MAC) Sedation
WOODCLIFF LAKE, N.J., Dec. 14 /PRNewswire/ -- Eisai Corporation of North
America today announced that the U.S. Food and Drug Administration (FDA) has
approved LUSEDRA(TM) (fospropofol disodium) Injection, an intravenous
sedative-hypnotic agent for monitored anesthesia care (MAC) sedation in adult
Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma
SAN FRANCISCO, Dec. 8 /PRNewswire/ -- Millennium: The Takeda Oncology Company today reported updated results based on extended follow up of patients from the large, international Phase III VISTA(1) trial showing continued survival improvement for patients with previously untreated multiple myeloma...
Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients
SAN FRANCISCO, Dec. 8 /PRNewswire/ -- Millennium: The Takeda Oncology
Company today reported updated results from two large, multi-center,
randomized Phase III clinical trials of VELCADE based combinations for the
induction treatment of transplant-eligible patients with previously untreated
Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients
SAN FRANCISCO, Dec. 7 /PRNewswire/ -- Millennium: The Takeda Oncology
Company today reported the Phase I results from a randomized, multi-center,
Company-sponsored Phase I/II study of VELCADE, dexamethasone, cyclophosphamide
and lenalidomide (VcDCR) in patients with previously untreated multiple
Neuralstem Licenses Cleveland Clinic Spinal Cord Injection Technology
ROCKVILLE, Md., Oct. 14 /PRNewswire-FirstCall/ -- Neuralstem Inc.,
(Amex: CUR ) today announced that it has licensed the rights to three
inventions from Cleveland Clinic pertaining to Targeted Spinal Cord
Therapeutics Delivery. All three inventions were developed by Dr. Nicholas
Boulis MD, fo...
Olanzapine Long-Acting Injection (LAI) Shown to Maintain Treatment Benefit in Schizophrenia for up to Six Months
BARCELONA, Spain, Sept. 2 /PRNewswire-FirstCall/ -- Final results from
a 24-week study presented today at a major medical meeting in Barcelona
suggest that investigational olanzapine long-acting injection
therapeutic doses showed a maintenance of treatment benefit for up to six
New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients
- Patients in the VELCADE, melphalan and prednisone arm demonstrated a
significant survival benefit as well as a 30 percent complete response -
CAMBRIDGE, Mass., Aug. 27 /PRNewswire/ -- Millennium: The Takeda
Oncology Company today announced the publication of results from the 682
BRIDION(R) (sugammadex) Injection - First and Only Selective Relaxant Binding Agent - Approved in European Union
BRIDION allows anesthesiologists to rapidly reverse both moderate and deep levels of muscle relaxation
First product approval from the Schering-Plough combination with Organon BioSciences
KENILWORTH, N.J., July 29 /PRNewswire-FirstCall/ -- Sch...
Olanzapine Long-Acting Injection (LAI) Data Presented at First Annual Schizophrenia International Research Society Conference
Efficacy and safety data were generally consistent with oral olanzapine with the exception of injection-related events
VENICE, Italy, June 23 /PRNewswire-FirstCall/ -- Results from
olanzapine long-acting injection
(LAI) clinical trials showed that the
efficacy and safety profile of...
New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study
Results Presented at the ADA's Annual Scientific Sessions
SAN FRANCISCO, June 7 /PRNewswire-FirstCall/ -- Sanofi-aventis
announced today that the results of the dose-finding study for its new
injectable diabetes compound AVE0010, a GLP-1 agonist, were presented at
the American Diabetes ...
Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss
Submitted to FDA for Stand-Alone Therapy in Q1 2008
SAN FRANCISCO, June 7 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals,
Inc. (Nasdaq: AMLN ) and Eli Lilly and Company (NYSE: LLY ) today announced
additional results from a study of patients with type 2 diabetes who were
Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma
CHICAGO, May 31 /PRNewswire/ -- Millennium Pharmaceuticals, The Takeda
Oncology Company, today announced the presentation of results from three
clinical trials of VELCADE based therapies that showed consistently high
complete remission(1) (CR) rates in patients with newly diagnosed multiple
VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma
-- IFM presents updated results from Phase III clinical trial --
CHICAGO, May 31 /PRNewswire/ -- Millennium Pharmaceuticals, The Takeda
Oncology Company, today announced the presentation of updated results from
a 482 patient, multi-center, randomized Phase III clinical trial, comparing
New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma
- Five Oral Presentations at ASCO Annual Meeting Will Further Demonstrate
the Strength of VELCADE Combinations in Front-line Multiple Myeloma -
CAMBRIDGE, Mass., May 16 /PRNewswire/ -- Millennium Pharmaceuticals,
The Takeda Oncology Company, today announced that new data from VELCADE
Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study
Separate Study Showed Significantly Improved Functioning Within Three Months
WASHINGTON, May 6 /PRNewswire-FirstCall/ -- Nearly half of patients
with schizophrenia fail to remain on their medication treatment, which can
result in a relapse of symptoms (1,2). To...
CorMatrix(R) Announces Intramyocardial Injection of Emulsified ECM Technology(TM) Demonstrates Enhanced Angiogenesis and Improved Cardiac Function in a Preclinical Model
Data Presented at annual American College of Cardiology (ACC) Scientific
Sessions Demonstrates Further Potential of Company's Platform ECM(TM) Technology
CHICAGO and ATLANTA, April 1, 2008 /PRNewswire/ -- CorMatrix
Cardiovascular, Inc., an Atlanta-based company...
Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm
DEERFIELD, Ill. and VANCOUVER, British Columbia, March 25
/PRNewswire-FirstCall/ -- Astellas Pharma US, Inc. and its co-development
partner Cardiome Pharma Corp. (Nasdaq: CRME ; TSX: COM) announced the first
pivotal Phase III study evaluating the investigational agent KYNAPID(TM)
Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkin's Lymphoma
- Building on Phase III registration trial of VELCADE and rituximab,
Millennium initiates new clinical trial with novel combination of VELCADE
with bendamustine and rituximab to further advance treatment of patients with follicular lymphoma -
CAMBRIDGE, Mass., Feb. 2...
FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
INDIANAPOLIS, Feb. 6 /PRNewswire-FirstCall/ -- The U.S. Food and Drug
Administration's (FDA) Psychopharmacologic Drugs Advisory Committee voted
that, with appropriate labeling around excessive sedation events,
Zyprexa(R) long-acting injection
(olanzapine LAI) has been shown to be
New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
- Three large, randomized Phase III trials of VELCADE in front-line
multiple myeloma to be featured as oral presentations at the American Society of Hematology (ASH) Annual Meeting -
CAMBRIDGE, Mass., Nov. 26 /PRNewswire-FirstCall/ -- Millennium
Pharmaceuticals, Inc. (Nasdaq:...
Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
DEERFIELD, Ill., Oct. 10 /PRNewswire/ -- Astellas Pharma US, Inc. today
announced that the investigational agent vernakalant hydrochloride
increased conversion to normal heart rhythm (sinus rhythm, or SR) in
patients with atrial fibrillation (AF) treated within 48 hours of the onset
Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
- Millennium on track to file sNDA in first quarter 2008 -
CAMBRIDGE, Mass., Sept. 18 /PRNewswire-FirstCall/ -- Millennium
Pharmaceuticals, Inc. (Nasdaq: MLNM ) today announced that the interim
analysis results of the large, international Phase III VISTA(1) trial in
patients with newly...
Study Demonstrates Restylane(R) Effect Lasted 18 Months in 97% of Patients With One Repeat Injection
SCOTTSDALE, Ariz., Feb. 10 /PRNewswire/ -- Recent clinical data show that Restylane (R) lasted 18 months in 97% of patients with one repeat injection. Restylane (R) is the only HA filler with an 18-month FDA-approved duration claim.
These data were generated in a controlled, randomiz...
Ikaria Completes Dosing of Phase 1a Clinical Study for IK-1001 (Sodium Sulfide) for Injection
CLINTON, N.J., May 19 /PRNewswire/ -- Ikaria Holdings, Inc., a fully
integrated critical care biotherapeutics company, announced today that it
has completed dosing of its Phase 1a trial for its drug candidate, IK-1001
(sodium sulfide) for injection.
The study was a Phase 1, randomized, singl...
MGI Pharma Announces Positive Results from a Pivotal Phase 3 Study
of Aquavan Injection in Patients Undergoing Bronchoscopy
MINNEAPOLIS--(BUSINESS WIRE)--Mar 20, 2007 - MGI PHARMA, INC.
(NASDAQ: MOGN), a biopharmaceutical company focused in oncology and
acute care, today announced that a randomized, double-blind,
multi-center, pivotal phase 3 trial of Aquavan(R) (fospropofol
for sedation of patients ...
Hana Biosciences Announces Data to be Presented On Talvesta
(Talotrexin) for Injection at The American Association for Cancer
Research Annual Meeting
SOUTH SAN FRANCISCO, Calif., April 11, 2007 (PRIME NEWSWIRE) --
Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused
on advancing cancer care, will present preclinical data for
Talvesta(tm) (talotrexin) for Injection
at the American Association
for Cancer Research 100th Annual Meeti...
Aquavan (Fospropofol Disodium) Injection Data Presented at
Digestive Disease Week 2007
MINNEAPOLIS, May 23, 2007 (BUSINESS WIRE) -- MGI PHARMA, INC.
(NASDAQ:MOGN), a biopharmaceutical company focused in oncology and
acute care, today announced the presentation of results of a
successful pivotal phase 3 trial of Aquavan(R) (fospropofol
in patients undergoing colon...
Velcade (bortezomib) for Injection Survival Data in Front-Line
Multiple Myeloma Patients to be Featured at 11th International
-- More than 70 abstracts highlight VELCADE efficacy in broad range
of patients and across continuum of care --
CAMBRIDGE, Mass., June 19, 2007 /PRNewswire-FirstCall/ --
Millennium Pharmaceuticals, Inc. today announced that data for
VELCADE, the market leading therapy with unsurpassed single-agent...
Velcade (bortezomib) for Injection Based Therapies Achieved
Survival Rates as High as 100 Percent in Newly Diagnosed Multiple
-- 100 percent response rate achieved with VELCADE, lenalidomide
KOS, Greece, June 28 /PRNewswire-FirstCall/ -- Millennium
Pharmaceuticals, Inc. (Nasdaq: MLNM) today reported on the
presentation of results from four clinical trials of VELCADE based
therapies that showed consist...
Velcade (Bortezomib) for Injection Based Therapies Produced
Complete Remission Rates as High as 54 Percent in Patients With
Previously Treated Multiple Myeloma
- 100 percent of patients treated with VELCADE, cyclophosphamide,
and prednisone alive at one year -
KOS, Greece, June 28, 2007 /PRNewswire-FirstCall/ -- Millennium
Pharmaceuticals, Inc. today reported on the presentation of results
from clinical trials of VELCADE based therapies that showed high
Velcade (bortezomib) for Injection Based Induction Therapy
Delivered High Post-Transplant Complete Remission Rate, a Critical
Marker for Increased Overall Survival
- New Data from Phase III Intergroupe Francophone du Myelome (IFM)
Trial Presented During IMW -
CAMBRIDGE, Mass., July 02, 2007 /PRNewswire-FirstCall/ --
Millennium Pharmaceuticals, Inc. today reported that new data were
presented on the comparative Phase III clinical trial evaluating a
Millennium Discovers Biomarkers Potentially Predictive of Response
to Velcade (Bortezomib) for Injection
- Findings Published in Blood Highlight Millennium Leadership in
Personalized Medicine and Could Strengthen the Role of VELCADE as
Foundation of Therapy in Broad Range of Multiple Myeloma Patients -
CAMBRIDGE, Mass., April 17, 2007 /PRNewswire-FirstCall/ --
Findings published in the April 15th iss...
Genta Announces Results of Phase 1 Study Using Genasense
Administered by Intermittent Subcutaneous Injection
Study Shows Safety and Pharmacokinetics Similar to IV Doses in
Phase 3 CLL Trial
BERKELEY HEIGHTS, N.J., June 06, 2007 /PRNewswire-FirstCall/ --
Genta Incorporated announced the publication of preliminary
clinical results that show the Company's lead anti-cancer drug,
Genasense(R) (oblimersen sodi...
Tiny Cup Attached to Eye Improves Drug Delivery For Retinal Diseases
...oes not hinder normal vision.
Currently, drugs for most retinal diseases are delivered either through an I.V. drip (i.e. systemically) or by an injection
into the eyeball (i.e. intravitreal), both of which pose risks for the patient.
For example, chemotherapy for retinoblastoma, a cancer affectin...
Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia
... than or equal to 5% and occurring at least twice as often as placebo) were injection
site reactions, somnolence/sedation, dizziness, akathisia and extrapyramida...common side effects in the treatment of schizophrenia were reactions at the injection
site, sleepiness, dizziness, feeling of inner restlessness, and abnormal mu...
British Woman Celebrates a Year of Living Cancer-Free
...tt went through a cancer treatment that changed her life -- and made history to boot.
Ms. Scott, 54, was the first person in the world to receive an injection
of tumor-activated natural killer (TaNK) cells as a treatment for leukemia.
Her doctors at the Royal Free Hospital in London recommended this e...
Study Shows Cancer Vaccines Led to Long-Term Survival for Patients with Metastatic Melanoma and to Long Periods of Disease Control After Completion of Therapy
...etastases despite various therapies. The vaccine treatment was well-tolerated, with most patients experiencing mild skin irritation and redness at the injection
"The one-year and projected five-year survival rates of 85% and 54%, respectively, are remarkable for melanoma patients with documented m...
Dirucotide Does Not Meet Primary Endpoint in Phase III MAESTRO-01 Trial in Secondary Progressive Multiple Sclerosis
... showed that dirucotide was generally well tolerated. There were no unexpected safety or tolerability issues. The most common side effect reported was injection
site reaction. More details of the MAESTRO-01 study results are expected to be presented at a medical conference later this year.
Lilly and Bio...
Injection Reverses Heart-Attack Damage
... on the same cellular pathway, Kuhn found.
"We applied periostin locally at the site of cardiac injury, but NRG1 works when given by systemic injection
- a very promising result that suggests it may be feasible to use this in the clinic to treat heart failure," says Kuhn, who won a first prize Young I...
Awardees for the 2009 Young Investigator Grant for Probiotics Research Announced
...on to producing the internationally recognized probiotic beverage, Yakult is also accredited in the pharmaceutical field for its development of Campto injection
(Camptosar), the first-line drug for colorectal cancer in the U.S. Yakult U.S.A. Inc., the subsidiary of Yakult Honsha Co., Ltd., is stationed in Tor...